SAN FRANCISCO, Sept. 19, 2011 /CNW/ - Cloud Dx, a division of Biosign
Technologies Inc. (TSXV: BIO), a medical device company focused on
non-invasive, cloud-based vital health monitoring, held its annual
shareholder meeting Monday, conducted by chairman of the board, Dr.
David Silver, where CEO, Dr. Scott Jenkins provided shareholders with a
look at the Cloud Dx target market. The meeting concluded with all
matters approved, including the election of Steven Bloom to the Board
of Directors and the continuation of the company's employee stock
option plan. Mr. Bloom was subsequently appointed as Chair of the Audit
Committee by the Board of Directors.
Dr. Jenkins provided the shareholders with a look at the patient and
disease management market globally and shared a snapshot of the Cloud
Dx competitive landscape as defined by its market model to reduce the
cost of healthcare utilization by providing an active cloud-based vital
health monitoring system that allows providers to deliver the best
quality of care to patients. To view Dr. Jenkins' presentation, please
click on the link below (or copy/type the link into the address line of
your browser): http://www.biosign.com/news.htm
Steven Bloom was elected to the Board of Directors and appointed by the
board to Chair the Audit Committee. Mr. Bloom is the Senior Vice
President, Finance at Kilmer Van Nostrand Co. Limited. He has served in
various financial leadership positions, including Partner and Chief
Financial Officer, Brightspark Capital; Chief Financial Officer, Think
Dynamics; Vice President, Finance, Descartes Systems Group; and
Manager, Ernst and Young.
Mr. Bloom is a Chartered Accountant and holds an Honors of Business
Administration degree from the University of Western Ontario - Richard
Ivey School of Business.
"We are very fortunate to have Steven Bloom on our board," says Dr.
Scott Jenkins, CEO, Cloud Dx. "Steven's extensive and diverse financial
experience will benefit our Audit Committee and bring a fresh
perspective to the board."
In addition to the approval of the employee stock option plan, the
Company granted an aggregate of 300,000 stock options pursuant to the
Company's stock option plan to Steven Bloom. 150,000 of such options
vest immediately and 150,000 vest over a two year period. These
options expire in 5 years and have an exercise price of $0.74 per share
and are subject to receipt of all necessary regulatory and shareholder
About Biosign Technologies Inc
Biosign Technologies Inc. (TSXV: BIO) provides biomedical systems. Cloud
Dx applications include intelligent systems for non-invasive monitoring
of common health risks associated with blood pressure, glucose, and
medication. Biosign technology combines measurement, analysis, and
tools for disease and patient management to support global vital health
monitoring. The UFIT® medical device delivers quality data collection
and analytics for clinical diagnostics, self-care, wellness, disease
state evaluation and management, and remote patient monitoring. For
more information visit: www.biosign.com.
This release contains forward-looking statements. Forward-looking
statements, without limitation, may contain the words believes,
expects, anticipates, estimates, intends, plans, or similar
expressions. Forward-looking statements are not guarantees of future
performance. They involve risks, uncertainties and assumptions and
Biosign's actual results could differ materially from those
anticipated. Forward looking statements are based on the opinions and
estimates of management at the date the statements are made, and are
subject to a variety of risks and uncertainties and other factors that
could cause actual events or results to differ materially from those
projected in the forward-looking statements. In the context of any
forward-looking information please refer to risk factors detailed in,
as well as other information contained in, Biosign's filings with
Canadian securities regulators (www.sedar.com).
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in policies of the TSX Venture Exchange) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE Biosign Technologies Inc.
For further information:
Cloud Dx Contact: